| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infectious Disease Transmission, Vertical | 64 | 2022 | 472 | 9.740 |
Why?
|
| HIV Infections | 102 | 2024 | 5097 | 7.510 |
Why?
|
| Viral Load | 33 | 2024 | 819 | 4.760 |
Why?
|
| HIV-1 | 37 | 2022 | 1260 | 3.880 |
Why?
|
| Early Diagnosis | 20 | 2021 | 82 | 3.560 |
Why?
|
| Infant | 69 | 2024 | 2244 | 3.110 |
Why?
|
| Polymerase Chain Reaction | 23 | 2021 | 260 | 3.020 |
Why?
|
| Anti-HIV Agents | 29 | 2024 | 1324 | 2.620 |
Why?
|
| Pregnancy Complications, Infectious | 25 | 2022 | 529 | 2.580 |
Why?
|
| Infant, Newborn | 49 | 2022 | 1479 | 2.570 |
Why?
|
| Humans | 111 | 2024 | 14537 | 2.170 |
Why?
|
| Female | 86 | 2024 | 9103 | 2.140 |
Why?
|
| HIV | 14 | 2021 | 380 | 2.060 |
Why?
|
| South Africa | 69 | 2024 | 7596 | 2.000 |
Why?
|
| Neonatal Screening | 6 | 2021 | 24 | 1.700 |
Why?
|
| Pregnancy | 43 | 2024 | 1862 | 1.680 |
Why?
|
| Reagent Kits, Diagnostic | 6 | 2021 | 56 | 1.440 |
Why?
|
| Anti-Retroviral Agents | 9 | 2024 | 551 | 1.420 |
Why?
|
| Blood | 6 | 2012 | 51 | 1.400 |
Why?
|
| Mass Screening | 7 | 2020 | 245 | 1.330 |
Why?
|
| Child | 23 | 2024 | 2242 | 1.250 |
Why?
|
| Male | 41 | 2024 | 6754 | 1.210 |
Why?
|
| HIV Core Protein p24 | 6 | 2013 | 18 | 1.110 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2021 | 132 | 1.110 |
Why?
|
| Point-of-Care Testing | 6 | 2023 | 71 | 1.110 |
Why?
|
| Sensitivity and Specificity | 18 | 2021 | 385 | 1.080 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2017 | 73 | 1.080 |
Why?
|
| Breast Feeding | 12 | 2021 | 120 | 1.070 |
Why?
|
| Nevirapine | 15 | 2019 | 146 | 1.050 |
Why?
|
| Retrospective Studies | 11 | 2024 | 799 | 0.920 |
Why?
|
| Adult | 23 | 2024 | 5913 | 0.870 |
Why?
|
| Counseling | 2 | 2022 | 143 | 0.850 |
Why?
|
| CD4 Lymphocyte Count | 10 | 2020 | 656 | 0.840 |
Why?
|
| Virology | 2 | 2013 | 13 | 0.830 |
Why?
|
| Developing Countries | 9 | 2019 | 400 | 0.810 |
Why?
|
| Child, Preschool | 21 | 2024 | 1748 | 0.810 |
Why?
|
| DNA, Viral | 8 | 2022 | 165 | 0.800 |
Why?
|
| Motivational Interviewing | 1 | 2022 | 10 | 0.780 |
Why?
|
| Postnatal Care | 2 | 2021 | 13 | 0.780 |
Why?
|
| Patient Compliance | 1 | 2022 | 120 | 0.740 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2024 | 187 | 0.720 |
Why?
|
| Young Adult | 12 | 2024 | 2498 | 0.690 |
Why?
|
| Adolescent | 15 | 2024 | 2985 | 0.660 |
Why?
|
| Cohort Studies | 12 | 2021 | 967 | 0.650 |
Why?
|
| Viremia | 3 | 2018 | 66 | 0.620 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2017 | 472 | 0.590 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2012 | 56 | 0.590 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 25 | 0.570 |
Why?
|
| Treatment Outcome | 7 | 2018 | 889 | 0.560 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2017 | 59 | 0.560 |
Why?
|
| Drug Resistance, Viral | 8 | 2023 | 278 | 0.540 |
Why?
|
| AIDS Serodiagnosis | 6 | 2019 | 44 | 0.530 |
Why?
|
| Mothers | 9 | 2020 | 195 | 0.510 |
Why?
|
| Postpartum Period | 6 | 2023 | 85 | 0.490 |
Why?
|
| Prevalence | 10 | 2020 | 1192 | 0.480 |
Why?
|
| Health Services Research | 1 | 2015 | 58 | 0.470 |
Why?
|
| Prenatal Care | 4 | 2021 | 147 | 0.470 |
Why?
|
| Models, Theoretical | 1 | 2014 | 80 | 0.460 |
Why?
|
| HIV Seropositivity | 4 | 2019 | 265 | 0.450 |
Why?
|
| Prospective Studies | 11 | 2020 | 1160 | 0.440 |
Why?
|
| Longitudinal Studies | 8 | 2024 | 435 | 0.430 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 1422 | 0.400 |
Why?
|
| Fetal Diseases | 1 | 2012 | 7 | 0.400 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2010 | 48 | 0.380 |
Why?
|
| HIV Protease Inhibitors | 4 | 2012 | 92 | 0.350 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 80 | 0.340 |
Why?
|
| Saliva | 1 | 2010 | 22 | 0.340 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 35 | 0.340 |
Why?
|
| HIV Antibodies | 2 | 2010 | 247 | 0.300 |
Why?
|
| Specimen Handling | 5 | 2020 | 105 | 0.300 |
Why?
|
| Time Factors | 7 | 2017 | 507 | 0.300 |
Why?
|
| RNA, Viral | 10 | 2021 | 303 | 0.290 |
Why?
|
| Immunoassay | 1 | 2007 | 28 | 0.290 |
Why?
|
| Blood Specimen Collection | 1 | 2007 | 13 | 0.290 |
Why?
|
| National Health Programs | 3 | 2019 | 78 | 0.280 |
Why?
|
| Medication Adherence | 3 | 2024 | 151 | 0.280 |
Why?
|
| Killer Cells, Natural | 4 | 2011 | 52 | 0.280 |
Why?
|
| Phlebotomy | 1 | 2006 | 6 | 0.280 |
Why?
|
| Lost to Follow-Up | 2 | 2017 | 62 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 127 | 0.270 |
Why?
|
| Age Distribution | 3 | 2020 | 107 | 0.270 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 280 | 0.270 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 91 | 0.260 |
Why?
|
| Risk Factors | 6 | 2022 | 1475 | 0.260 |
Why?
|
| Preventive Health Services | 1 | 2005 | 17 | 0.250 |
Why?
|
| Infant Care | 1 | 2005 | 10 | 0.250 |
Why?
|
| Body Fluids | 1 | 2005 | 5 | 0.250 |
Why?
|
| Algorithms | 2 | 2021 | 106 | 0.240 |
Why?
|
| Child Health | 2 | 2022 | 77 | 0.230 |
Why?
|
| Program Evaluation | 1 | 2004 | 89 | 0.230 |
Why?
|
| Chemoprevention | 2 | 2017 | 33 | 0.230 |
Why?
|
| Social Stigma | 1 | 2024 | 80 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 370 | 0.220 |
Why?
|
| Research Design | 1 | 2004 | 124 | 0.220 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2019 | 118 | 0.210 |
Why?
|
| Genotype | 5 | 2017 | 442 | 0.210 |
Why?
|
| Data Warehousing | 1 | 2022 | 1 | 0.200 |
Why?
|
| NAD+ Nucleosidase | 1 | 2002 | 2 | 0.200 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 3 | 0.200 |
Why?
|
| Data Accuracy | 1 | 2022 | 9 | 0.200 |
Why?
|
| Middle Aged | 2 | 2021 | 3601 | 0.200 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 217 | 0.200 |
Why?
|
| Ritonavir | 3 | 2012 | 137 | 0.200 |
Why?
|
| Antigens, CD | 1 | 2002 | 26 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2008 | 150 | 0.200 |
Why?
|
| Standard of Care | 1 | 2022 | 30 | 0.200 |
Why?
|
| Models, Biological | 2 | 2012 | 77 | 0.200 |
Why?
|
| Milk, Human | 1 | 2021 | 23 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2010 | 151 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 2 | 2024 | 125 | 0.190 |
Why?
|
| Receptors, KIR | 2 | 2011 | 23 | 0.190 |
Why?
|
| Syphilis, Congenital | 1 | 2021 | 13 | 0.180 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 253 | 0.180 |
Why?
|
| Syphilis | 1 | 2021 | 14 | 0.180 |
Why?
|
| Choristoma | 1 | 2000 | 1 | 0.180 |
Why?
|
| Somatosensory Cortex | 1 | 2000 | 1 | 0.180 |
Why?
|
| Biotin | 1 | 2000 | 2 | 0.180 |
Why?
|
| Autoimmunity | 1 | 2000 | 5 | 0.180 |
Why?
|
| Neurons | 1 | 2000 | 23 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2000 | 24 | 0.180 |
Why?
|
| Live Birth | 1 | 2020 | 5 | 0.180 |
Why?
|
| Viral Proteins | 2 | 2010 | 30 | 0.170 |
Why?
|
| Age Factors | 1 | 2021 | 370 | 0.170 |
Why?
|
| Laboratories, Hospital | 1 | 2019 | 2 | 0.170 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 79 | 0.170 |
Why?
|
| Income | 1 | 2019 | 85 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 115 | 0.160 |
Why?
|
| Lopinavir | 4 | 2012 | 137 | 0.160 |
Why?
|
| Disease Management | 2 | 2017 | 74 | 0.160 |
Why?
|
| Caregivers | 1 | 2019 | 76 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2018 | 26 | 0.150 |
Why?
|
| Maternal Health Services | 2 | 2015 | 52 | 0.150 |
Why?
|
| Hospitals, Maternity | 1 | 2017 | 4 | 0.140 |
Why?
|
| Drug Monitoring | 2 | 2021 | 55 | 0.140 |
Why?
|
| Topography, Medical | 1 | 2017 | 2 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 23 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 40 | 0.140 |
Why?
|
| Patient Identification Systems | 1 | 2017 | 4 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 33 | 0.140 |
Why?
|
| Community Health Services | 1 | 2017 | 58 | 0.140 |
Why?
|
| Incidence | 2 | 2012 | 685 | 0.140 |
Why?
|
| Contact Tracing | 1 | 2017 | 48 | 0.130 |
Why?
|
| Infant Mortality | 2 | 2013 | 97 | 0.130 |
Why?
|
| Cytokines | 3 | 2009 | 107 | 0.120 |
Why?
|
| Poverty | 2 | 2005 | 152 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 7 | 0.110 |
Why?
|
| Pyrimidinones | 2 | 2010 | 24 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 188 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2009 | 195 | 0.110 |
Why?
|
| Flow Cytometry | 3 | 2009 | 67 | 0.100 |
Why?
|
| Mutation, Missense | 2 | 2011 | 65 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 27 | 0.100 |
Why?
|
| Desiccation | 2 | 2008 | 15 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2012 | 57 | 0.090 |
Why?
|
| Chemokine CCL3 | 2 | 2008 | 23 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2011 | 15 | 0.090 |
Why?
|
| HIV Protease | 1 | 2011 | 22 | 0.090 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 52 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 563 | 0.090 |
Why?
|
| Maternal Exposure | 1 | 2010 | 14 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 23 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2011 | 50 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2010 | 17 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 22 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 65 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2009 | 20 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 33 | 0.080 |
Why?
|
| Self Report | 2 | 2019 | 114 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 41 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2008 | 23 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 411 | 0.080 |
Why?
|
| Pediatrics | 1 | 2007 | 17 | 0.070 |
Why?
|
| Chemokines, CC | 1 | 2007 | 15 | 0.070 |
Why?
|
| Health Facilities | 2 | 2017 | 40 | 0.070 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 322 | 0.070 |
Why?
|
| Health Resources | 1 | 2007 | 66 | 0.070 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2010 | 324 | 0.070 |
Why?
|
| Animals | 2 | 2018 | 1081 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 279 | 0.060 |
Why?
|
| Erythropoietin | 2 | 2002 | 8 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 149 | 0.060 |
Why?
|
| Infant, Premature | 2 | 2002 | 56 | 0.060 |
Why?
|
| Diagnosis, Oral | 1 | 2005 | 2 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2005 | 13 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2005 | 89 | 0.060 |
Why?
|
| Bias | 1 | 2004 | 15 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2011 | 176 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2005 | 115 | 0.060 |
Why?
|
| Cost Savings | 1 | 2004 | 7 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 13 | 0.060 |
Why?
|
| Antigens, Viral | 1 | 2004 | 21 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2005 | 167 | 0.060 |
Why?
|
| Health Personnel | 1 | 2005 | 231 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2005 | 256 | 0.050 |
Why?
|
| Africa South of the Sahara | 2 | 2016 | 353 | 0.050 |
Why?
|
| HIV Seronegativity | 2 | 2019 | 52 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2023 | 175 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 25 | 0.050 |
Why?
|
| Anemia, Neonatal | 1 | 2002 | 2 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2002 | 6 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2002 | 2 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 11 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2002 | 35 | 0.050 |
Why?
|
| African Americans | 1 | 2002 | 47 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 109 | 0.050 |
Why?
|
| Prognosis | 1 | 2002 | 199 | 0.050 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 239 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 106 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 9 | 0.050 |
Why?
|
| Carbocyanines | 1 | 2000 | 1 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 1 | 0.050 |
Why?
|
| Thalamic Nuclei | 1 | 2000 | 1 | 0.050 |
Why?
|
| Dextrans | 1 | 2000 | 2 | 0.050 |
Why?
|
| Neural Pathways | 1 | 2000 | 2 | 0.050 |
Why?
|
| Motor Cortex | 1 | 2000 | 2 | 0.050 |
Why?
|
| Biomarkers | 1 | 2002 | 327 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 13 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 39 | 0.040 |
Why?
|
| Mice | 1 | 2000 | 135 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 51 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2011 | 35 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 154 | 0.040 |
Why?
|
| Nurses, Neonatal | 1 | 2019 | 1 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 1999 | 3 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 23 | 0.040 |
Why?
|
| Lactation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 64 | 0.040 |
Why?
|
| Adolescent Health | 1 | 2019 | 15 | 0.040 |
Why?
|
| Government Programs | 1 | 2019 | 30 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 181 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 1999 | 49 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2019 | 24 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 31 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 14 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 171 | 0.040 |
Why?
|
| Alkynes | 1 | 2019 | 117 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 123 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 156 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1998 | 2 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 1998 | 2 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 1998 | 2 | 0.040 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1998 | 2 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 1998 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1998 | 4 | 0.040 |
Why?
|
| Benzoxazines | 1 | 2019 | 123 | 0.040 |
Why?
|
| Urban Population | 1 | 2000 | 257 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 122 | 0.040 |
Why?
|
| Hospitals | 1 | 2018 | 103 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 45 | 0.040 |
Why?
|
| Thailand | 1 | 2017 | 26 | 0.040 |
Why?
|
| United Kingdom | 1 | 2017 | 33 | 0.040 |
Why?
|
| Botswana | 1 | 2017 | 24 | 0.040 |
Why?
|
| Reference Values | 3 | 2002 | 64 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 16 | 0.040 |
Why?
|
| Anemia, Megaloblastic | 1 | 1997 | 1 | 0.040 |
Why?
|
| Bone Marrow | 1 | 1997 | 19 | 0.040 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 1997 | 1 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1997 | 1 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2016 | 11 | 0.030 |
Why?
|
| Apoptosis | 1 | 1997 | 40 | 0.030 |
Why?
|
| DNA | 1 | 1997 | 73 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 62 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 59 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 203 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 225 | 0.030 |
Why?
|
| Health Policy | 1 | 2017 | 140 | 0.030 |
Why?
|
| Home Childbirth | 1 | 2015 | 5 | 0.030 |
Why?
|
| Maternal Age | 1 | 2015 | 22 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2015 | 18 | 0.030 |
Why?
|
| Parity | 1 | 2015 | 19 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 2015 | 15 | 0.030 |
Why?
|
| Zidovudine | 1 | 2015 | 59 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2013 | 6 | 0.030 |
Why?
|
| Tuberculosis | 1 | 1999 | 543 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2013 | 22 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 96 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 23 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.020 |
Why?
|
| Warfarin | 1 | 2012 | 19 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 52 | 0.020 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 111 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2011 | 12 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 72 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 40 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 41 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 29 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 33 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 39 | 0.020 |
Why?
|
| Ethionamide | 1 | 2010 | 9 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 125 | 0.020 |
Why?
|
| Lamivudine | 1 | 2010 | 89 | 0.020 |
Why?
|
| Stavudine | 1 | 2010 | 78 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 14 | 0.020 |
Why?
|
| Isoniazid | 1 | 2010 | 110 | 0.020 |
Why?
|
| Rifampin | 1 | 2010 | 197 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 6 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 263 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2008 | 13 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 10 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2007 | 27 | 0.020 |
Why?
|
| Africa | 1 | 2007 | 376 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 480 | 0.020 |
Why?
|
| Mutation | 1 | 2006 | 306 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 22 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 27 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 73 | 0.010 |
Why?
|
| Fetal Hemoglobin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 125 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2002 | 15 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2002 | 11 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 40 | 0.010 |
Why?
|
| Skin Tests | 1 | 1999 | 14 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1998 | 24 | 0.010 |
Why?
|
| Acute Disease | 1 | 1998 | 105 | 0.010 |
Why?
|
| Interphase | 1 | 1997 | 1 | 0.010 |
Why?
|
| Mitosis | 1 | 1997 | 1 | 0.010 |
Why?
|
| Ploidies | 1 | 1997 | 2 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 3 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1997 | 3 | 0.010 |
Why?
|